Knowledge Distillery

Since the start of the vaccination campaign, the development of COVID-19 has been reported in persons who have received one or both doses of mRNA-1273…

• General interest

  •  

     

     

     

     

     

     

     

     

     

     

     

• Academic/Scientific

  •  

     

     

     

     

     

     

     

     

     

     

    …

CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2.

In this phase 1, double-blind, placebo-controlled, block-randomised trial the authors aimed to assess the safety and immunogenicity of an…

Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination.

Since vaccination against COVID-19 became available, risks related to vaccinating patients with MS need to be carefully assessed.

Studies on the real-life effect of the BNT162b2 vaccine for Coronavirus Disease 2019 (COVID-19) prevention are urgently needed.

Following the emergency use authorisation of the Pfizer–BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in…

SARS-CoV-2 vaccine rollout has coincided with the spread of variants of concern. In this article the authors investigated if single dose vaccination,…

BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute…

NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length…

The objective of this case-control study was to estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S…